Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis Interventions: Drug: Personalized extended interval dosing of natalizumab; Drug: Standard interval dosing Sponsors: VU University Medical Center; Stichting MS Research; Innovatiefonds Zorgverzekeraard Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials